+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

FDA approves Fragmin (dalteparin sodium) first anticoagulant for pediatric patients to treat potentially life-threatening blood clots

The U.S. Food and Drug Administration has approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of…

read more

Dengvaxia, the first vaccine approved by FDA for the prevention of dengue disease caused by all dengue virus serotypes

The U.S. Food and Drug Administration has announced the approval of Dengvaxia, the first vaccine approved for the prevention of…

read more

FDA approves Benlysta (belimumab) first treatment for pediatric patients with lupus

The U.S. Food and Drug Administration has approved Benlysta (belimumab) intravenous (IV) infusion for treatment of children with systemic lupus…

read more

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb has announced results from pooled analyses of survival data from four studies in patients with previously-treated advanced non-small cell…

read more

Dovato (dolutegravir and lamivudine), a new complete regimen for HIV-infected patients who have never received antiretroviral treatment

The U.S. Food and Drug Administration has approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of…

read more

Mayzent (siponimod) tablets approved by FDA to treat adults with relapsing forms of multiple sclerosis (MS)

The U.S. Food and Drug Administration has approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis…

read more

Zynteglo, New gene therapy to treat rare inherited blood condition

EMA has recommended granting a marketing authorisation in the European Union for a genetically modified product for beta-thalassaemia, a rare inherited blood…

read more

Merck has announced the FDA approval of its Mavenclad (cladribine) tablets in various forms of multiple sclerosis (MS).

The U.S. Food and Drug Administration has approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in…

read more

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

The U.S. Food and Drug Administration has approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the…

read more

New indication for Dupixent (dupilumab) as add on treatment for patients with severe asthma

EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Dupixent (dupilumab) as an add-on maintenance treatment for adult…

read more

Ondexxya (andexanet alfa), first antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ondexxya (andexanet alfa). This medicine…

read more

Waylivra (volanesorsen), first treatment for rare disease characterised by high levels of triglycerides in blood

The European Medicines Agency has recommended granting a conditional marketing authorisation (CMA) for Waylivra (volanesorsen), the first medicine for the treatment of…

read more

CONTACT US

ELIXI International SA

 

Vicolo Oldelli 1
6830 Chiasso / Switzerland

Tel./Fax +41 91 6822040

Your name (required)

Your e-mail (required)

Your message